AbbVie Profit Meets Analysts’ Estimates on Humira Sales
This article is for subscribers only.
AbbVie Inc. reported fourth-quarter profit that met analysts’ estimates on increased revenue from the company’s top drug, Humira for rheumatoid arthritis.
Earnings excluding one-time items were 82 cents a share, matching the average of nine estimates compiled by Bloomberg. The company, which split from parent Abbott Laboratories last year, forecast 2014 profit of $3 to $3.10 a share, North Chicago, Illinois-based AbbVie said today in a statement. Analysts had estimated $3.13.